Mycobacterium avium complex 50S ribosomal subunit (MAC 50S ribosome)

The Mycobacterium avium complex (MAC) 50S ribosomal subunit is the larger component of the 70S bacterial ribosome in species such as Mycobacterium avium and Mycobacterium intracellulare. It is a complex ribonucleoprotein assembly consisting of 23S ribosomal RNA (rRNA), 5S rRNA, and numerous ribosomal proteins, which together catalyze peptide bond formation during translation (NCBI: Mycobacterium avium, 2024). This subunit is the primary pharmacological target for macrolide antibiotics, including clarithromycin and azithromycin, which are the foundational treatments for MAC infections (StatPearls: Mycobacterium Avium Complex, 2023). By binding to the 23S rRNA, these drugs block the exit tunnel for nascent proteins, effectively halting bacterial growth. MAC is a significant pathogen responsible for chronic lung disease in patients with underlying pulmonary conditions and disseminated infections in immunocompromised individuals. Clinical management is often complicated by the emergence of resistance, typically driven by point mutations in the 23S rRNA gene that prevent drug binding (Griffith et al., 2007, Am J Respir Crit Care Med). Consequently, the 50S subunit remains a focal point for the development of new antimicrobial agents and diagnostic tools for monitoring resistance.

Other names

50S ribosomal subunit of Mycobacterium avium complexMAC 50S ribosomeLarge ribosomal subunit of MACMycobacterium avium 50S ribosome

Drugs targeting the MAC 50S ribosomal subunit, primarily macrolides, bind to the 23S ribosomal RNA (rRNA) near the peptidyl transferase center. This binding physically obstructs the ribosomal exit tunnel, thereby inhibiting the elongation of the nascent polypeptide chain and leading to the dissociation of peptidyl-tRNA (Wilson, 2014, Nat Rev Microbiol). Oxazolidinones like linezolid also bind to the 50S subunit but interfere with the formation of the initiation complex (StatPearls: Linezolid, 2023).